2:50 PM
 | 
Apr 03, 2019
 |  BC Extra  |  Politics & Policy

FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market

Richard Pazdur, director of FDA’s Oncology Center of Excellence, is urging Chinese companies to bring PD-1/PD-L1 inhibitors to the U.S. market and undercut the prices charged by multinational pharmas.

Chinese companies competing in the U.S. on the price of PD-1s “could potentially be a great thing for everyone because we haven’t seen the major western pharmaceutical companies moving on price,” Pazdur said at the American Association for Cancer Research meeting. He spoke from the audience during the question and answer portion of a session titled “East meets West: Chinese pharma explores Western markets.”

FDA could approve a drug, including a PD-1/PD-L1 inhibitor, based solely on clinical data from China, Pazdur said. He reported that on a visit to China last summer, he was frequently asked if FDA would accept applications with clinical...

Read the full 644 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >